GlassScriptPhysician profile
Cassidy Kujala
NPI 1336918002
$1,804.66
in general payments reported to CMS, 2019-2025
28 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,067 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.40 | 2024-2025 | |
| Daiichi Sankyo INC. | $197.13 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $182.75 | 2024-2025 | |
| Lilly USA, LLC | $117.48 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $115.99 | 2024-2025 | |
| Pfizer INC. | $108.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.22 | 2024-2025 | Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $105.70 | 2024 | Keytruda, Welireg |
| Genentech USA, INC. | $63.81 | 2024 | Venclexta, Polivy, Lunsumio |
| Regeneron Healthcare Solutions, INC. | $58.09 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $48.96 | 2024 | Ninlaro, Hyqvia |
| Sobi, INC | $46.05 | 2025 | |
| Karyopharm Therapeutics INC. | $42.33 | 2025 | Xpovio |
| Exelixis INC. | $40.39 | 2024 | Cabometyx |
| Tempus Ai, INC | $27.32 | 2025 | Xt Cdx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.15 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $27.08 | 2024 | Carvykti |
| Jazz Pharmaceuticals INC. | $25.11 | 2024 | |
| Glaxosmithkline, LLC. | $25.11 | 2025 | Jemperli |
| Adaptive Biotechnologies Corporation | $23.62 | 2025 | Clonoseq |
| Incyte Corporation | $23.03 | 2024 | Jakafi |
| Coherus Oncology, INC. | $20.62 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.39 | 2024 | Monoferric |
| Sumitomo Pharma America, INC. | $18.39 | 2025 | Orgovyx |
| Adc Therapeutics America, INC. | $17.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.95 | 2024 | |
| Celgene Corporation | $13.09 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Kujala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.